Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- 12-hour Night Shift Work for Nurses Increasing: JNA Survey
May 27, 2002
- Eiken: Sales Up 2.5% to \21.3 Bil., Net Profits Up 44.4% to \1.2 Bil.
May 27, 2002
- Neoral Reduces Kidney Rejection Rates: MO2ART Study
May 27, 2002
- Worker Consultation Service Receives 5,398 Calls: LWC Survey
May 27, 2002
- Kainos: Automatic ELISA System for Microplates
May 27, 2002
- Will the FY2002 Medical Fee Revision Promote Use of Generics? - Strategies of Major GE Makers - （1）
May 27, 2002
- Improvement of Nurse Training Recommended
May 27, 2002
- WEBSITE NEWS
May 27, 2002
- Will the FY2002 Medical Fee Revision Promote Use of Generics? - Strategies of Major GE Makers - （2）
May 27, 2002
- Nat'l Exam for Physicians to Be Made More Accessible to the Handicapped
May 27, 2002
- Terumo: Sales Up 6.3% to \187,082 Mil.
May 27, 2002
- Wholesalers to Assist Makers in Immediate PMS
May 27, 2002
- General Risk Managers Appointed at All Nat'l Univ. Hospitals
May 27, 2002
- Olympus: New Digital Microscope "MIC-D"
May 27, 2002
- Drug Sales Up 3.5% in FY2001: CR&C
May 27, 2002
- GL on Subarachnoidal Hemorrhage Compiled
May 27, 2002
- AstraZeneca PLC: 1st Qtr Sales Up 13% to US$4,421 Mil.
May 27, 2002
- Otsuka Pharma Factory Sues Shionogi Claiming Infringement of Design Right
May 27, 2002
- Registration for J-WIND Increases Sharply
May 27, 2002
- Acarbose Prevents Type 2 Diabetes: STOP-NIDDM Study
May 27, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…